BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Wednesday in a venture round to develop compounds for rare genetic diseases.

The company in-licenses preclinical and clinical stage assets from academia and pharma, and houses them in individual subsidiaries. BridgeBio, which has disclosed 10 of its subsidiaries, raised a $135 million venture round in September (see "Orphan Opportunity")...